This article provides a detailed guide for researchers and drug developers on utilizing Adeno-Associated Virus (AAV) vectors to deliver base editors for precise gene correction.
This article explores the cutting-edge methodology of using recombinant Adeno-Associated Virus (AAV) vectors to deliver CRISPR crRNA arrays for in vivo cancer modeling.
This article provides a comprehensive, up-to-date comparison of the specificity of the three primary genome-editing platforms: CRISPR, TALENs, and ZFNs.
Achieving prime editing efficiencies beyond 80% represents a critical frontier for therapeutic applications.
This article provides a comprehensive overview of lentiviral vectors for delivering prime editing guide RNAs (pegRNAs), a critical component for achieving efficient and precise genome modifications.
This article provides a comprehensive exploration of the CRISPR-Cas9 mechanism of action, tailored for researchers, scientists, and drug development professionals.
This article provides a comprehensive guide for researchers and drug development professionals on validating therapeutic gene editing in the clinical landscape of 2025.
This article provides a comprehensive overview of the piggyBac (PB) transposon system as a powerful non-viral platform for stable genomic integration of gene editors and therapeutic transgenes.
This article provides a comprehensive comparison of CRISPR-Cas9 and Cas12a systems, with a dedicated focus on their application in multiplex genome editing for biomedical research and therapeutic development.
This article provides a comprehensive comparison of insertion/deletion (indel) formation rates across major gene-editing platforms, including CRISPR-Cas9, TALENs, ZFNs, base editors, and prime editors.